Novocure Ltd (NVCR) Reaches $17.73 After 9.00% Down Move, Atossa Genetics (ATOS) Shorts Increased By 4%

July 6, 2017 - By Darrin Black

Atossa Genetics Incorporated (NASDAQ:ATOS) had an increase of 4% in short interest. ATOS’s SI was 301,800 shares in July as released by FINRA. Its up 4% from 290,200 shares previously. With 112,500 avg volume, 3 days are for Atossa Genetics Incorporated (NASDAQ:ATOS)’s short sellers to cover ATOS’s short positions. The SI to Atossa Genetics Incorporated’s float is 8.62%. About 260,972 shares traded or 28.20% up from the average. Atossa Genetics Inc (NASDAQ:ATOS) has declined 86.91% since July 6, 2016 and is downtrending. It has underperformed by 103.61% the S&P500.

The stock of Novocure Ltd (NASDAQ:NVCR) is a huge mover today! About 323,676 shares traded. Novocure Ltd (NASDAQ:NVCR) has declined 0.43% since July 6, 2016 and is downtrending. It has underperformed by 17.13% the S&P500.The move comes after 8 months negative chart setup for the $1.60 billion company. It was reported on Jul, 6 by Barchart.com. We have $16.13 PT which if reached, will make NASDAQ:NVCR worth $144.00 million less.

Among 5 analysts covering NovoCure (NASDAQ:NVCR), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. NovoCure has $43 highest and $16 lowest target. $27.20’s average target is 53.41% above currents $17.73 stock price. NovoCure had 6 analyst reports since October 27, 2015 according to SRatingsIntel. The firm has “Outperform” rating by Wedbush given on Tuesday, October 27. On Friday, July 29 the stock rating was maintained by Wedbush with “Outperform”. The stock of Novocure Ltd (NASDAQ:NVCR) has “Hold” rating given on Wednesday, December 2 by Deutsche Bank. Barclays Capital initiated the stock with “Underweight” rating in Tuesday, January 19 report. The rating was initiated by JMP Securities on Tuesday, October 27 with “Market Outperform”. The stock of Novocure Ltd (NASDAQ:NVCR) earned “Overweight” rating by JP Morgan on Tuesday, October 27.

Analysts await Novocure Ltd (NASDAQ:NVCR) to report earnings on July, 27. They expect $-0.21 EPS, up 56.25% or $0.27 from last year’s $-0.48 per share. After $-0.21 actual EPS reported by Novocure Ltd for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

NovoCure Limited is a commercial-stage oncology company. The company has market cap of $1.60 billion. The Firm is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. It currently has negative earnings. The Company’s TTFields delivery system is used for the treatment of glioblastoma and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.